Objectives-The beneficial effect of oestrogens on bone mineral density in women with osteoporosis is well known. Patients with rheumatoid arthritis (RA) are at risk for osteoporosis. A study was therefore set up to investigate the effects of adjuvant oestrogen treatment on bone metabolism and bone mineral density in postmenopausal women with RA. Methods-Forty postmenopausal women with active RA were admitted to a placebo controlled, double blind study investigating the beneficial effect of adjuvant oestradiols or placebo on bone metabolism and bone mineral density. Thirty three patients completed 52 weeks of treatment. Results-At the start both treatment groups were comparable for ali parameters. In the oestrogen group serum concentrations of osteocalcin decreased and concentrations of sex hormone binding globulin increased during the study. Bone mineral density measured by dual energy x ray absorptiometry increased significantly in the lumbar vertebral spine and femoral neck in the oestrogen group compared with the placebo group. Conclusions-This study shows that the use of adjuvant oestrogens in postmenopausal women with active RA increases bone mineral density.
Rheumatoid arthritis (RA) is often associated with considerable periarticular and generalised bone loss which may lead to an increased incidence of fractures.1-' Several mechanisms are thought to contribute to bone loss in women with RA. Joint inflammation may lead to periarticular bone loss due to immobility and the release of local bone resorbing factors.4 6 Factors such as physical inactivity due to active RA, the use of glucocorticoids, and postmenopausal status may all contribute to generalised bone loss. 1`4 After the menopause bone remodelling is increased with accelerated bone loss. Treatment with oestrogens can prevent this bone loss and in retrospective studies oestrogens reduce the incidence of vertebral7 and peripheral fractures8 in healthy postmenopausal women. Epidemiological and immunological evidence suggests that female hormones may have a beneficial effect on the course of RA. 9 To investigate the effects of oestrogens on bone metabolism and bone mineral density in postmenopausal women with RA, we conducted a randomised double blind placebo controlled study for one year.
Patients and methods

PATIENTS
After approval of the ethical committee 40 postmenopausal women with adult onset RA were admitted to the study; no contraindication for oestrogen treatment was found in any of the patients. Patients were considered to be postmenopausal when there had been no menstruation in the previous year. Patients using corticosteroids or hormone replacement treatment were not allowed to participate in the study. None of the patients used any drug known to influence bone metabolism. All patients fulfilled the revised criteria for RA'0 and had active disease which met at least three of the following criteria: more than six painful joints; more than three swollen joints; erythrocyte sedimentation rate >28 mm/hour; and morning stiffness for longer than 45 minutes. Disease modifying antirheumatic drugs were used in constant dosages for at least three months before the start of the study and were kept stable during the trial.
STUDY DESIGN
In a double blind controlled study we compared 2 We did not find a significant change in these ratios in the oestrogen group, but the two ratios seemed to decrease.
Adjuvant oestrogen treatment had a beneficial effect on the bone mineral density of the lumbar spine and femoral neck. An increase of bone mineral density in the oestrogen group compared with the placebo group was seen after six months of treatment. An increase in bone mass was followed by a plateau in the lumbar spine and femoral neck, an effect also reported in other studies using drugs such as etidronate and calcitonin with an effect against bone resorption.'3 14 An explanation for this phenomenon is that the resorption cavities are filled, increasing the bone mineral content, after a decrease in bone remodelling. After the empty resorption cavities are filled, no further increment in bone mass occurs and the plateau phase is observed.'5 The bone mineral density in the lumbar spine increased more than in the femoral neck; this is because the lumbar spine consists of trabecular bone only, which is metabolically more active than cortical bone, the main substance of the femoral neck. An effect of oestrogens on bone metabolism is thus detected earlier in the lumbar spine than in the femoral neck.
The precise mechanisms by which oestrogens influence bone metabolism are still unclear but the net result is an increase in bone mineral density. This must be due to a change in the balance between bone formation and resorption, leading to a stronger inhibition of bone resorption than bone formation. Oestrogens may act directly on osteoblasts since receptors for oestrogens have been shown,'6 but an indirect regulatory mechanism through growth factors has also been proposed. 7 Recruitment of osteoblasts and osteoclasts from precursor cells is regulated by local and systemic growth factors. It has been suggested that replacement treatment with oestrogens leads to a decrease in plasma insulin-like growth factor I and an increase in plasma growth hormone.
In conclusion, this study shows that adjuvant treatment with oestrogens (2 mg oestradiol valerate) given for one year in postmenopausal women with RA influences bone metabolism and significantly increases the bone mineral density in the lumbar spine and femoral neck.
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